V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients.

ABSTRACT:

Background

Anemia is common among end-stage renal disease (ESRD) patients who undergone hemodialysis. The total reduction of red blood cell (RBC) count is associated with poor prognosis in these patients. Although erythropoietin (EPO) has been used as an effective treatment for ESRD patients with anemia, a large number of patients still present poor responses to EPO treatment.

Methods

We measured T-cell receptor sequencing profiles, including length of complementarity-deteremining region 3 (CDR3), intra- and inter-group (EPO resistant vs. responsive) clonotype diversity, V(D)J usage profiles and V-J combinations from ESRD patients and to investigate the correlation between these features and EPO treatment efficacy.

Results

Our results revealed statistical significance

SUBMITTER: Wong HS 

PROVIDER: S-EPMC5504791 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature